Aspira Women's Health Appoints New Directors, Adjusts Executive Pay

Ticker: AWHL · Form: 8-K · Filed: 2025-02-10T00:00:00.000Z

Sentiment: neutral

Topics: management-change, executive-compensation, board-of-directors

TL;DR

Aspira Women's Health adds 2 directors and updates CEO/CFO pay packages.

AI Summary

Aspira Women's Health Inc. announced on February 5, 2025, changes in its board of directors and executive compensation. Specifically, the company elected two new directors, Dr. David E.I. Enoch and Ms. Jennifer L. McNeely, to its Board of Directors, effective February 5, 2025. Additionally, the company entered into new employment agreements with its Chief Executive Officer, Ms. R. Wendie Lachance, and Chief Financial Officer, Mr. David L. Clapper, detailing their compensation and severance packages.

Why It Matters

The appointment of new directors and adjustments to executive compensation can signal strategic shifts or changes in governance for Aspira Women's Health, potentially impacting future performance and investor confidence.

Risk Assessment

Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts or strategic realignments that may carry inherent risks.

Key Players & Entities

Aspira Women's Health Inc. (company) — Registrant
Dr. David E.I. Enoch (person) — Newly Elected Director
Ms. Jennifer L. McNeely (person) — Newly Elected Director
Ms. R. Wendie Lachance (person) — Chief Executive Officer
Mr. David L. Clapper (person) — Chief Financial Officer
February 5, 2025 (date) — Effective date of director appointments and event date

FAQ

Who were the new directors appointed to the Board of Directors?

Dr. David E.I. Enoch and Ms. Jennifer L. McNeely were elected to the Board of Directors.

When were the new directors' appointments effective?

The appointments of Dr. David E.I. Enoch and Ms. Jennifer L. McNeely were effective February 5, 2025.

Which executives entered into new employment agreements?

The company entered into new employment agreements with its Chief Executive Officer, Ms. R. Wendie Lachance, and Chief Financial Officer, Mr. David L. Clapper.

What is the filing date of this 8-K report?

This 8-K report was filed on February 10, 2025.

What was the former name of Aspira Women's Health Inc.?

Aspira Women's Health Inc. was formerly known as VERMILLION, INC. and CIPHERGEN BIOSYSTEMS INC.

From the Filing

0001493152-25-005666.txt : 20250210 0001493152-25-005666.hdr.sgml : 20250210 20250210170035 ACCESSION NUMBER: 0001493152-25-005666 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250205 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20250210 DATE AS OF CHANGE: 20250210 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aspira Women's Health Inc. CENTRAL INDEX KEY: 0000926617 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330595156 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34810 FILM NUMBER: 25606483 BUSINESS ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 BUSINESS PHONE: 512-519-0400 MAIL ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 FORMER COMPANY: FORMER CONFORMED NAME: VERMILLION, INC. DATE OF NAME CHANGE: 20070824 FORMER COMPANY: FORMER CONFORMED NAME: CIPHERGEN BIOSYSTEMS INC DATE OF NAME CHANGE: 20000316 FORMER COMPANY: FORMER CONFORMED NAME: ABIOTIC SYSTEMS DATE OF NAME CHANGE: 19950407 8-K 1 form8-k.htm false 0000926617 0000926617 2025-02-05 2025-02-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549       FORM 8-K       CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2025       Aspira Women’s Health Inc. (Exact name of Registrant as Specified in Its Charter)       Delaware   001-34810   33-0595156 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   12117 Bee Caves Road Building III Suite 100     Austin , Texas   78738 (Address of Principal Executive Offices)   (Zip Code)   Registrant’s Telephone Number, Including Area Code: 512 519-0400     (Former Name or Former Address, if Changed Since Last Report)       Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001 per share   AWH   The Nasdaq Stock Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certa